Navigation Links
Selexis Lubris Partnership Advances Difficult-to-Express Protein Towards Clinic
Date:6/27/2012

GENEVA, June 27, 2012 /PRNewswire/ -- Selexis SA, a global life sciences company for drug discovery, cell line development and scale-up to manufacturing of therapeutic proteins, announced today that its US-based customer, Lubris LLC, has achieved over 1 g/L per liter yield in manufacturing production runs of LUB-13-04 as measured by Lubris' CMO partner. LUB-13-04 is a proprietary construct of the recombinant human protein lubricin (Proteoglycan 4 protein, rLubricin) which is expressed from the SURE CHO-M cell line generated with the Selexis SUREtechnology Platform™. LUB-13-04 is in pre-clinical development for dry eye syndrome and osteoarthritis.

(Logo: http://photos.prnewswire.com/prnh/20120627/LA31604LOGO)

Lubricin is a large endogenous complex glycoprotein composed of 40% carbohydrates, originally identified as a lubricating component of synovial fluid. While lubricin has been most actively evaluated for the treatment for osteoarthritis, it is also being studied in dry eye, dry mouth, surgical adhesions and other unmet medical needs.

"The results from the Selexis/Lubris partnership are quite impressive," said Igor Fisch, PhD, CEO of Selexis SA. "We continue to demonstrate that the SUREtechnology Platform™ has a major impact on the economics of manufacturing biologics by significantly increasing the manufacturing cell line's stability and productivity."

"Recombinant lubricin has been proven to be difficult to express efficiently at levels that ensured commercial viability. This is the first reported case of expression levels exceeding 1 g/L for lubricin (or lubricin-like proteins). We chose Selexis based on its track record for overcoming expression bottlenecks with difficult-to-express proteins, and generating fully documented cell lines used for clinical manufacturing," said Ed Truitt, CEO of Lubris. "These results represent a major development milestone as they demonstrate that our technology can be manufactured cost effectively in an increasingly challenging economic environment. We are on schedule to begin clinical trials in 2013 with our Swiss based European partner with our treatment for dry eye disease which represents a significant unmet medical need in a multi-billion dollar ophthalmic market."

About Selexis SA

Headquartered in Geneva, Switzerland, Selexis SA is a global life science company with innovative technologies and world-class expert services for drug discovery, cell line development and scale-up to manufacturing of therapeutic proteins. The Company's SUREtechnology Platform™ is based on Selexis Genetic Elements™ -- novel DNA-based elements that control the dynamic organization of chromatin within all mammalian cells and allow for higher and more stable expression of recombinant proteins. Selexis has generated over 1,300 cell lines being used in a variety of programs from drug discovery to late-stage clinical trials. The Company anticipates three products manufactured from cell lines using the Selexis SUREtechnology Platform™ to be launched in 2012.

For more information:
- Visit http://www.selexis.com
- Follow us on Twitter @selexisSA
- Become a fan at www.facebook.com/SelexisSA

About Lubris, LLC.

Lubris, LLC, is a specialty life science company focused on development of promising new treatments utilizing the lubricating and anti-adhesive protein, lubricin. Efforts are focused on applications within ophthalmology, arthritis and joint pain, oral health, surgical applications and women's health. Lubris, LLC was formed in 2011 from the merger of Singularis, Inc. (a San Diego-based start-up spun out of Harvard & UCSD) and Tribos, LLC (a Boston-based start-up spun out of Brown University).

For more information:
- Visit http://www.lubris.net

Contact: Robert Meister, 602-953-1716, robert.meister@selexis.com


'/>"/>
SOURCE Selexis SA
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Scotland-based Innova Partnerships Ltd. Opens Boston Office
2. Medifast Announces International Expansion Into Mexico Through Strategic Partnership with Medix
3. Lilly Expands Strategic Partnership with Chinese Manufacturer Novast to Serve Chinese Patients with High-Quality Branded Generic Medicines
4. HUYA Bioscience International Engages In Partnership With Zhuhai Sanzao Science and Technology Industrial Park
5. Bayer Partnership Delivers Industry-First Dose Management Offering
6. VitaTech Adds New Capacity for Production and Customer Interface, Attributes Growth to Strategic Customer Partnerships
7. Medical Guardian Announces Social Media Partnership with Senior Citizen Charity
8. Rigel Advances Asthma Programs: Two Inhaled Drug Candidates Take Aim at Acute and Chronic Lung Disease
9. Polaris Group Lead Therapeutic Candidate ADI-PEG 20 Demonstrates Potential Anticancer Activity in Various Metastatic Sarcomas and Bladder Cancers That Are Deficient in Key Metabolic Protein, and Enhanced Effects with Combination Therapy in Melanoma
10. Cell Therapeutics Aequus BioPharma Validates its Proprietary GlycoPolymer Technology for the Extension of the Half-life of Therapeutic Protein Drugs
11. Ventana licenses Gen-Probe IP for measuring ERG protein in prostate cancer patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 2016 The Academy of Managed Care Pharmacy ... that would allow biopharmaceutical companies to more easily share ... formulary and coverage decisions, a move that addresses the ... The recommendations address restrictions in the sharing ... drug label, a prohibition that hinders decision makers from ...
(Date:6/24/2016)... , June 24, 2016 ... Market by Type (Standard Pen Needles, Safety Pen Needles), ... (Insulin, GLP-1, Growth Hormone), Mode of Purchase (Retail, Non-Retail) ... MarketsandMarkets, This report studies the market for the forecast ... to reach USD 2.81 Billion by 2021 from USD ...
(Date:6/23/2016)... 2016  MedSource announced today that it has ... solution of choice.  This latest decision demonstrates MedSource,s ... their clients by offering a state-of-the-art electronic data ... nowEDC as the EDC platform of choice in ... "nowEDC has long been a preferred EDC platform ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... June 24, 2016 , ... ... Scientific Sessions in Dallas that it will receive two significant new grants to ... came as PHA marked its 25th anniversary by recognizing patients, medical professionals and ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with ... Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a ...
(Date:6/24/2016)... ... 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ... raise to $12 an hour by 2020 and then adjusting it yearly to increase at ... the minimum wage, assure the wage floor does not erode again, and make future increases ...
(Date:6/24/2016)... ... June 24, 2016 , ... EB Medicine presented its first-ever ... Medicine conference in Ponte Vedra Beach, FL. The awards honor the outstanding work ... Practice and Pediatric Emergency Medicine Practice. , “With this award, we recognize ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... The Grove Investment Group (TGIG), has initiated cultivation and processing operations at its ... Vegas and Pahrump, Nevada. , Puradigm is the manufacturer of a complete system ...
Breaking Medicine News(10 mins):